MIS+rtPA for ICH Evacuation (MISTIE)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this trial is to determine the safety of using a combination of minimally invasive surgery and clot lysis with rt-PA to remove intracerebral hemorrhage (ICH). The ICES arm of the trial will determine the safety of endoscopic surgery to remove ICH.
| Condition | Intervention | Phase |
|---|---|---|
|
Intracerebral Hemorrhage |
Drug: MIS+Cathflo Activase (drug) Procedure: Intraoperative stereotactic CT-Guided Endoscopic Surgery |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Minimally Invasive Surgery Plus rtPA for Intracerebral Hemorrhage Evacuation |
- Mortality [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
- Procedure related mortality [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
- Incidence of cerebritis, meningitis [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
- Rate of rebleeding [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
- Rate of clot size reduction at Days 4-5 determined by CT scans [ Time Frame: 7 days ] [ Designated as safety issue: No ]
- 90-, 180-, & 365-day GOS, eGOS, Rankin, Stroke Impact Scale [ Time Frame: 365 days ] [ Designated as safety issue: No ]
- Post-operative size reduction [ Time Frame: 10 days ] [ Designated as safety issue: No ]
| Enrollment: | 143 |
| Study Start Date: | August 2005 |
| Study Completion Date: | April 2013 |
| Primary Completion Date: | August 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| No Intervention: Medical Managment | |
|
Active Comparator: MISTIE Surgical Management
Minimally invasive surgery with clot lysis with rt-PA.
|
Drug: MIS+Cathflo Activase (drug)
The intervention is a comparison of the safety and preliminary effectiveness of investigational minimally invasive surgery to place a catheter into an intracerebral hemorrhage blood clot and subsequent administration in sequential tiers of 0.3, 1.0, or 3.0 mg of recombinant tissue plasminogen activator, rt-PA, CathFlo®) through the catheter once every eight hours for up to 72 hours with best medical care.
Other Name: rtPA
|
|
Active Comparator: ICES Surgical Management
Endoscopic removal of ICH
|
Procedure: Intraoperative stereotactic CT-Guided Endoscopic Surgery |
Detailed Description:
The purpose of this trial is to determine the safety of using a combination of minimally invasive surgery and clot lysis with rt-PA to remove intracerebral hemorrhage (ICH). The procedure is to use image-based surgery (MRI or CT) to provide catheter access to ICH for the intervention, which is a one-time clot aspiration followed by instillation of rt-PA over 72 hours.
The Intraoperative stereotactic CT-guided Endoscopic Surgery (ICES) arm of the trial will determine the safety, feasibility and effectiveness of endoscopic surgery to remove ICH.
We propose to test if these interventions facilitate more rapid and complete recovery of function and decreased mortality from this condition compared to conventional medical management without subjecting the patient to craniotomy. The specific objective of this trial is to test the safety of these interventions and assess their ability to remove blood clot from brain tissue.
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age 18-80
- GCS < 14 or a NIHSS > or equal to 6
- Spontaneous supratentorial ICH > or equal to 20cc
- Symptoms less than 12 hours prior to diagnostic CT scan (an unknown time of symptom onset is exclusionary)
- Intention to initiate surgery within 48 hours after diagnostic CT
- First dose can be given within 54 hours after diagnostic CT (delays for post surgical stabilization of catheter bleeding or because of unanticipated surgical delay are acceptable with approved waiver from the coordinating center) (Does not apply to ICES Tier)
- Six-hour clot size equal to the most previous clot size + 5 cc (as determined by an additional CT scan at least 6 hours after the initial stability scan (A*B*C)/2 method)
- SBP < 200 mmHg sustained for 6 hours recorded closest to time of randomization
- Historical Rankin score of 0 or 1
- Negative pregnancy test
Exclusion Criteria:
- Infratentorial hemorrhage (any involvement of the midbrain or lower brainstem as demonstrated by radiograph or complete third nerve palsy)
- Patients with platelet count < 100,000, INR > 1.4, or an elevated PT or APTT (reversal of coumadin is permitted but the patient must not require coumadin during the acute hospitalization). Irreversible coagulopathy either due to medical condition or prior to randomization
- Clotting disorders
- Any concurrent serious illness that would interfere with the safety assessments including hepatic, renal, gastroenterologic, respiratory, cardiovascular, endocrinologic, immunologic, and hematologic disease
- Patients with a mechanical valve
- Patients with unstable mass or evolving intracranial compartment syndrome
- Ruptured aneurysm, AVM, vascular anomaly
- Greater than 80 years (higher incidence of amyloid)
- Under 18 years of ag e (high incidence of occult vascular malformation)
- Pregnant (positive pregnancy test) or lactating females (likelihood of altered coagulation function associated with the high estrogen/progesterone state)
- Irreversibly impaired brainstem function (bilateral fixed, dilated pupils and extensor motor posturing), GCS less than or equal to 4
- Historical Rankin score greater than or equal to 2
- Intraventricular hemorrhage requiring external ventricular drainage
- Internal bleeding, involving retroperitoneal sites, or the gastrointestinal, genitourinary, or respiratory tracts (Does not apply to ICES Tier)
- Superficial or surface bleeding, observed mainly at vascular puncture and access sites (e.g., venous cutdowns, arterial punctures) or site of recent surgical intervention (Does not apply to ICES Tier)
- Known risk for embolization, including history of left heart thrombus, mitral stenosis with atrial fibrillation, acute pericarditis, and subacute bacterial endocarditis (Does not apply to ICES Tier)
- In the investigator's opinion, the patient is unstable and would benefit from a specific intervention rather than supportive care plus or minus MIS+rtPA
- Prior enrollment in the study
- Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated
- Participation in another simultaneous trial of ICH treatment.
Contacts and Locations
Hide Study Locations| United States, Alabama | |
| University of Alabama at Birmingham | |
| Birmingham, Alabama, United States | |
| United States, Arizona | |
| Barrow Neurosurgical Associates | |
| Phoenix, Arizona, United States, 85013 | |
| United States, California | |
| University of California Los Angeles | |
| Los Angeles, California, United States, 90095 | |
| Stanford University | |
| Palo Alto, California, United States, 94034 | |
| University of California, San Diego | |
| San Diego, California, United States, 92103 | |
| United States, Connecticut | |
| Hartford Hospital | |
| Hartford, Connecticut, United States, 06102 | |
| United States, District of Columbia | |
| Georgetown University | |
| Washington, District of Columbia, United States, 20007 | |
| United States, Florida | |
| Mayo Clinic | |
| Jacksonville, Florida, United States, 32216 | |
| United States, Illinois | |
| Rush University | |
| Chicago, Illinois, United States, 60612 | |
| University of Chicago | |
| Chicago, Illinois, United States, 60637 | |
| NorthShore University Health System | |
| Evanston, Illinois, United States, 60201 | |
| United States, Maryland | |
| Johns Hopkins University/Bayview Medical Center | |
| Baltimore, Maryland, United States, 21287 | |
| University of Maryland Medical Systems | |
| Baltimore, Maryland, United States, 21201 | |
| United States, Michigan | |
| Henry Ford Health System | |
| Detroit, Michigan, United States, 48202 | |
| United States, New Jersey | |
| New Jersey Medical School | |
| Edison, New Jersey, United States, 08818 | |
| United States, New York | |
| Mt. Sinai Medical Center | |
| New York, New York, United States, 10029 | |
| United States, Ohio | |
| University of Cincinnati | |
| Cincinnati, Ohio, United States, 45267 | |
| Case Western University | |
| Cleveland, Ohio, United States, 44106 | |
| United States, Pennsylvania | |
| Temple University | |
| Philadelphia, Pennsylvania, United States, 19140 | |
| Thomas Jefferson University | |
| Philadelphia, Pennsylvania, United States, 19107 | |
| University of Pittsburgh Medical Center | |
| Pittsburgh, Pennsylvania, United States, 15213 | |
| Allegheny General Hospital | |
| Pittsburgh, Pennsylvania, United States, 15212 | |
| United States, South Carolina | |
| Medical University of South Carolina | |
| Charleston, South Carolina, United States, 29425 | |
| United States, Texas | |
| University of Texas, Houston | |
| Houston, Texas, United States, 77030 | |
| University of Texas HSC, San Antonio | |
| San Antonio, Texas, United States, 78229 | |
| United States, Virginia | |
| Virginia Commonwealth University | |
| Richmond, Virginia, United States, 23298 | |
| Canada, Quebec | |
| Montreal Neurological Institute at McGill University | |
| Montreal, Quebec, Canada, H3A 2B4 | |
| Germany | |
| University of Heidelberg | |
| Heidelberg, Germany, 69117 | |
| United Kingdom | |
| Newcastle General Hospital | |
| Newcastle, United Kingdom | |
| Study Chair: | Daniel F. Hanley, MD | Johns Hopkins University |
| Principal Investigator: | Mario Zuccarello, MD | University of Cincinnati |
| Principal Investigator: | Paul Vespa, MD | University of California, Los Angeles |
More Information
Additional Information:
No publications provided
| Responsible Party: | Daniel Hanley, MD, Johns Hopkins University |
| ClinicalTrials.gov Identifier: | NCT00224770 History of Changes |
| Other Study ID Numbers: | ICH01, R01NS046309 |
| Study First Received: | September 21, 2005 |
| Last Updated: | June 5, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Hemorrhage Cerebral Hemorrhage Pathologic Processes Intracranial Hemorrhages Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Vascular Diseases |
Cardiovascular Diseases Tissue Plasminogen Activator Fibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Cardiovascular Agents Therapeutic Uses Hematologic Agents |
ClinicalTrials.gov processed this record on June 17, 2013